HC Wainwright Reiterates Buy Rating for Bolt Biotherapeutics (NASDAQ:BOLT)

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 79.03% from the stock’s current price.

Several other brokerages also recently issued reports on BOLT. Zacks Research downgraded Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $34.00.

Bolt Biotherapeutics Trading Down 3.5%

Shares of BOLT stock opened at $3.91 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57. The stock has a fifty day simple moving average of $5.40 and a two-hundred day simple moving average of $5.36. The firm has a market capitalization of $7.51 million, a PE ratio of -0.22 and a beta of 0.94. Bolt Biotherapeutics has a 52-week low of $3.91 and a 52-week high of $9.66.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($3.84) EPS for the quarter, beating the consensus estimate of ($4.27) by $0.43. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $0.67 million. Bolt Biotherapeutics had a negative return on equity of 85.03% and a negative net margin of 433.74%. On average, analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several large investors have recently made changes to their positions in BOLT. Renaissance Technologies LLC lifted its position in shares of Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares in the last quarter. T3 Companies LLC purchased a new position in Bolt Biotherapeutics during the 4th quarter valued at approximately $208,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Bolt Biotherapeutics during the 4th quarter valued at approximately $112,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics in the 3rd quarter worth approximately $89,000. Finally, Shay Capital LLC bought a new stake in Bolt Biotherapeutics in the 3rd quarter worth approximately $85,000. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.